PCM Encore LLC Takes $583,000 Position in Stryker Corporation $SYK

Posted by Brenda Bartman on Aug 21st, 2026

PCM Encore LLC acquired a new stake in Stryker Corporation (NYSE:SYK – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,851 shares of the medical technology company’s stock, valued at approximately $583,000.

A number of other institutional investors have also recently added to or reduced their stakes in SYK. Norges Bank purchased a new position in Stryker in the fourth quarter valued at about $1,822,272,000. Auto Owners Insurance Co lifted its position in shares of Stryker by 35,047.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock valued at $1,024,444,000 after acquiring an additional 2,906,448 shares during the period. Flossbach Von Storch SE purchased a new stake in shares of Stryker during the 2nd quarter worth approximately $464,506,000. Wellington Management Group LLP boosted its stake in shares of Stryker by 22.6% during the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after acquiring an additional 1,198,665 shares in the last quarter. Finally, Corient Private Wealth LLC grew its holdings in shares of Stryker by 104.4% in the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after acquiring an additional 1,146,998 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Down 3.5%

Shares of NYSE SYK opened at $327.97 on Friday. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The firm has a market cap of $125.80 billion, a P/E ratio of 33.99, a price-to-earnings-growth ratio of 2.17 and a beta of 0.76. The firm’s 50 day moving average price is $326.64 and its 200 day moving average price is $332.66. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.

Stryker (NYSE:SYK – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s payout ratio is 36.48%.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the sale, the director directly owned 2,251,375 shares in the company, valued at $765,692,637.50. This trade represents a 2.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 665,370 shares of company stock valued at $216,238,501. Corporate insiders own 4.60% of the company’s stock.

Analyst Ratings Changes

SYK has been the subject of several research reports. Piper Sandler reduced their price objective on Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Needham & Company LLC lowered their target price on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Weiss Ratings restated a “hold (c)” rating on shares of Stryker in a research report on Friday, July 31st. Evercore set a $350.00 price target on Stryker in a research note on Monday, July 6th. Finally, Argus set a $370.00 price objective on shares of Stryker in a research report on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $386.28.

Read Our Latest Stock Analysis on Stryker

Stryker Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.